Bin-Yan Zhong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2258390/publications.pdf

Version: 2024-02-01

933447 752698 44 524 10 20 citations g-index h-index papers 45 45 45 592 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. Journal of Clinical and Translational Hepatology, 2022, 10, 740-747.	1.4	7
2	Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World Journal of Gastrointestinal Surgery, 2022, 14, 528-537.	1.5	5
3	Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. American Journal of Roentgenology, 2021, 217, 933-943.	2.2	22
4	Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. CardioVascular and Interventional Radiology, 2021, 44, 63-72.	2.0	5
5	Prognostic nomogram on admission predicting progression for patients with nonsevere COVID-19. Fundamental Research, 2021, 1, 111-116.	3.3	O
6	Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 615133.	3.5	5
7	Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	14
8	Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. Translational Oncology, 2021, 14, 101034.	3.7	20
9	Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 602700.	2.8	6
10	Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Molecular Biosciences, 2021, 8, 618050.	3.5	6
11	Application of radiomics in hepatocellular carcinoma: A review. Artificial Intelligence in Medical Imaging, 2021, 2, 64-72.	0.6	O
12	Single-Centre Retrospective Training Cohort Using Artificial Intelligence for Prognostic Prediction of Encephalopathy, Mortality, and Liver Dysfunction after Early TIPS Creation. CardioVascular and Interventional Radiology, 2021, 44, 1597-1608.	2.0	9
13	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671.	1.5	46
14	Performance of artificial intelligence for prognostic prediction with the albumin-bilirubin and platelet-albumin-bilirubin for cirrhotic patients with acute variceal bleeding undergoing early transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e153-e160.	1.6	5
15	Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 657512.	2.8	16
16	125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. CardioVascular and Interventional Radiology, 2020, 43, 196-203.	2.0	6
17	Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. Frontiers in Oncology, 2020, 10, 593292.	2.8	23
18	Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Frontiers in Oncology, 2020, 10, 1196.	2.8	34

#	Article	IF	CITATIONS
19	Changes in IR from 2007 to 2017 in China. Journal of Vascular and Interventional Radiology, 2020, 31, 1449-1452.	0.5	1
20	Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Oncology, 2020, 10, 525461.	2.8	15
21	Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis. Phlebology, 2020, 35, 589-596.	1.2	3
22	Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE. CardioVascular and Interventional Radiology, 2020, 43, 1460-1467.	2.0	6
23	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology and Hepatology, 2019, 4, 721-730.	8.1	105
24	Risk Prediction for Early Biliary Infection after Percutaneous Transhepatic Biliary Stent Placement in Malignant Biliary Obstruction. Journal of Vascular and Interventional Radiology, 2019, 30, 1233-1241.e1.	0.5	10
25	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 330-338.	0.5	24
26	Bariatric Arterial Embolization for Overweight Patients: A New Exploration for Ideal Patients?. CardioVascular and Interventional Radiology, 2019, 42, 1048-1049.	2.0	0
27	Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective. Chinese Clinical Oncology, 2019, 8, 60-60.	1.2	6
28	Research progress of bariatric embolization for treatment of obesity. Chinese Medical Journal, 2019, 132, 880-882.	2.3	1
29	Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients. Obesity Surgery, 2018, 28, 907-915.	2.1	44
30	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology, 2018, 288, 636-636.	7.3	0
31	Response to Letter of "Left Gastric Artery Embolization for Weight Loss—a Deadend Procedure― Obesity Surgery, 2018, 28, 3625-3626.	2.1	1
32	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2018, 41, 1867-1876.	2.0	1
33	Bariatric Arterial Embolization for Obesity: A Review of Early Clinical Evidence. CardioVascular and Interventional Radiology, 2018, 41, 1639-1647.	2.0	8
34	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology, 2017, 284, 583-592.	7.3	19
35	Does Sorafenib Fit for All?. Radiology, 2017, 284, 919-921.	7.3	0
36	Risk Prediction of New Adjacent Vertebral Fractures After PVP for Patients with Vertebral Compression Fractures: Development of a Prediction Model. CardioVascular and Interventional Radiology, 2017, 40, 277-284.	2.0	27

#	Article	IF	CITATIONS
37	Reply to: Percutaneous Vertebral Augmentation for the Treatment of Symptomatic Schmorl's Nodes: Our Viewpoint and Experience. Pain Physician, 2017, 3, E474-E475.	0.4	О
38	Percutaneous Vertebroplasty for Symptomatic Schmorl's Nodes: 11 Cases with Long-term Follow-up and a Literature Review. Pain Physician, 2017, 20, 69-76.	0.4	7
39	Reply to: Percutaneous Vertebral Augmentation for the Treatment of Symptomatic Schmorl's Nodes: Our Viewpoint and Experience. Pain Physician, 2017, 20, E474-E475.	0.4	O
40	Nomogram for Predicting Intradiscal Cement Leakage Following Percutaneous Vertebroplasty in Patients with Osteoporotic Related Vertebral Compression Fractures. Pain Physician, 2017, 20, E513-E520.	0.4	4
41	A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. Journal of Vascular and Interventional Radiology, 2016, 27, 1288-1297.	0.5	6
42	ANVCFV Score System: Assessment for Probability of New Vertebral Compression Fractures after Percutaneous Vertebroplasty in Patients with Vertebral Compression Fractures. Pain Physician, 2015, 18, E1047-57.	0.4	5
43	Impact of COVID-19 Pandemic on Intervals and Outcomes of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	1
44	Deep Learning Predicts Overall Survival of Patients with Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib: A Multicenter Study. SSRN Electronic Journal, 0, , .	0.4	0